Ethinylestradiol/segesterone acetate
Ethinylestradiol/segesterone acetate (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains ethinylestradiol, an estrogen, and segesterone acetate, a progestin.[1] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.[1][2]
Combination of | |
---|---|
Ethinylestradiol | Estrogen |
Segesterone acetate | Progestogen |
Clinical data | |
Trade names | Annovera |
Other names | EE/SGA; EE/SA |
Routes of administration | Vaginal ring |
Identifiers | |
KEGG |
Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for 7 days, during which the user experiences a period (withdrawal bleeding.) This can be repeated 13 times, for one full year of use.[3] Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed to a patient and can be stored at temperatures up to 30 degrees Celsius.[4]
The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for use in the United States on 10 August 2018.[2]
See also
References
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
- https://ir.therapeuticsmd.com/news-releases/news-release-details/therapeuticsmd-announces-fda-approval-annoveratm-segesterone
- "FDA approves new vaginal ring for one year of birth control".
- "FDA prescribing information for Annovera" (PDF).
Progestogens (and progestins) |
| ||||
---|---|---|---|---|---|
Antiprogestogens |
| ||||
|
ER |
| ||||||
---|---|---|---|---|---|---|---|
GPER |
| ||||||
|
PR |
| ||||||
---|---|---|---|---|---|---|---|
mPR (PAQR) |
| ||||||
|